PT2493466T - Nova utilização antifúngica do cabazitaxel - Google Patents
Nova utilização antifúngica do cabazitaxelInfo
- Publication number
- PT2493466T PT2493466T PT107820391T PT10782039T PT2493466T PT 2493466 T PT2493466 T PT 2493466T PT 107820391 T PT107820391 T PT 107820391T PT 10782039 T PT10782039 T PT 10782039T PT 2493466 T PT2493466 T PT 2493466T
- Authority
- PT
- Portugal
- Prior art keywords
- cabazitaxel
- new antifungal
- antifungal use
- new
- antifungal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25616009P | 2009-10-29 | 2009-10-29 | |
| US29390310P | 2010-01-11 | 2010-01-11 | |
| US35588810P | 2010-06-17 | 2010-06-17 | |
| US35583410P | 2010-06-17 | 2010-06-17 | |
| US36992910P | 2010-08-02 | 2010-08-02 | |
| US38393310P | 2010-09-17 | 2010-09-17 | |
| US38996910P | 2010-10-05 | 2010-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2493466T true PT2493466T (pt) | 2021-03-29 |
Family
ID=43567614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107820391T PT2493466T (pt) | 2009-10-29 | 2010-10-27 | Nova utilização antifúngica do cabazitaxel |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US8927592B2 (https=) |
| EP (1) | EP2493466B1 (https=) |
| JP (2) | JP5566466B2 (https=) |
| KR (1) | KR101712231B1 (https=) |
| CN (1) | CN102770131A (https=) |
| AR (1) | AR078824A1 (https=) |
| AU (4) | AU2010310986A1 (https=) |
| BR (1) | BR112012011457A2 (https=) |
| CA (1) | CA2779009A1 (https=) |
| CR (1) | CR20120204A (https=) |
| DK (1) | DK2493466T3 (https=) |
| EA (1) | EA024186B1 (https=) |
| EC (1) | ECSP12011836A (https=) |
| ES (1) | ES2862340T3 (https=) |
| GT (1) | GT201200123A (https=) |
| IL (3) | IL219443A0 (https=) |
| MA (1) | MA33767B1 (https=) |
| MX (1) | MX336339B (https=) |
| MY (1) | MY164086A (https=) |
| NI (1) | NI201200071A (https=) |
| PE (1) | PE20121429A1 (https=) |
| PH (1) | PH12012500848A1 (https=) |
| PL (1) | PL2493466T3 (https=) |
| PT (1) | PT2493466T (https=) |
| SG (1) | SG10201810928SA (https=) |
| SV (1) | SV2012004192A (https=) |
| TN (1) | TN2012000188A1 (https=) |
| TW (2) | TWI533866B (https=) |
| UY (1) | UY32987A (https=) |
| WO (1) | WO2011051894A1 (https=) |
| ZA (1) | ZA201203123B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
| CN102770131A (zh) | 2009-10-29 | 2012-11-07 | 安万特医药股份有限公司 | 卡巴他赛的新颖抗肿瘤用途 |
| JP2014514306A (ja) * | 2011-04-12 | 2014-06-19 | プラス・ケミカルス・エスアー | 固体形態のカバジタキセル及びその製造方法 |
| CN102503913B (zh) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法 |
| JP6025861B2 (ja) * | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
| WO2013111157A1 (en) * | 2012-01-03 | 2013-08-01 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
| CN104583189A (zh) | 2012-07-31 | 2015-04-29 | 永信药品工业股份有限公司 | 非晶型的卡巴利他索 |
| TW201438714A (zh) * | 2013-03-04 | 2014-10-16 | Aventis Pharma Sa | 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途 |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| PT3258931T (pt) * | 2015-02-17 | 2020-09-23 | Univ Erasmus Med Ct Rotterdam | Utilização do cabazitaxel no tratamento do cancro da próstata |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| EP3509569A1 (en) | 2016-09-07 | 2019-07-17 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| US10195214B2 (en) | 2017-03-01 | 2019-02-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
| US20210088505A1 (en) * | 2017-04-07 | 2021-03-25 | La Jolla Institute For Allergy And Immunology | Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof |
| US20250017891A1 (en) * | 2023-07-04 | 2025-01-16 | Twi Pharmaceuticals, Inc. | Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5005588A (en) | 1989-10-13 | 1991-04-09 | David Rubin | Method for increasing tumor sensitivity to chemotherapy |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| ZA94128B (en) | 1993-02-01 | 1994-08-19 | Univ New York State Res Found | Process for the preparation of taxane derivatives and betalactam intermediates therefor |
| FR2732340B1 (fr) | 1995-03-27 | 1997-04-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
| US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
| FR2745814B1 (fr) | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
| US6346543B1 (en) | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| WO2000010547A2 (en) | 1998-08-20 | 2000-03-02 | Aventis Pharma S.A. | New use of taxoid derivatives |
| US6403634B1 (en) | 1999-01-13 | 2002-06-11 | Aventis Pharma S.A. | Use of taxoid derivatives |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| SI1493556T1 (sl) | 2003-07-02 | 2006-02-28 | Scheuten Glasgroep Bv | Postopek za pripravo protipozarne zasteklitve |
| EP1498120A1 (en) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
| FR2859996B1 (fr) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| GB0425854D0 (en) | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
| SG156625A1 (en) | 2004-12-08 | 2009-11-26 | Aventis Pharma Inc | Method for measuring resistance or sensitivity to docetaxel |
| EP1700596A1 (en) | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| FR2922107B1 (fr) | 2007-10-10 | 2010-02-26 | Aventis Pharma Sa | Nouvelles compositions a base de taxoides |
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| EP2177630A1 (en) * | 2008-10-02 | 2010-04-21 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| CN103932972A (zh) | 2009-03-30 | 2014-07-23 | 天蓝制药公司 | 聚合物-药剂缀合物、颗粒、组合物和相关使用方法 |
| FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
| US20110160159A1 (en) | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| CN102770131A (zh) | 2009-10-29 | 2012-11-07 | 安万特医药股份有限公司 | 卡巴他赛的新颖抗肿瘤用途 |
| ES2621613T3 (es) | 2009-11-04 | 2017-07-04 | Emcure Pharmaceuticals Limited | Un proceso mejorado para la preparación de derivados de taxano |
| AU2010321533A1 (en) | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| WO2011124669A1 (en) | 2010-04-08 | 2011-10-13 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| WO2011130317A2 (en) | 2010-04-13 | 2011-10-20 | Amplyx Pharmaceuticals Inc. | Therapeutic agents having reduced toxicity |
| AU2011239569B2 (en) | 2010-04-16 | 2014-07-24 | Baylor College Of Medicine | Method for treating solid tumors |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| EP3808345A1 (en) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
-
2010
- 2010-10-27 CN CN2010800600528A patent/CN102770131A/zh active Pending
- 2010-10-27 MY MYPI2012001871A patent/MY164086A/en unknown
- 2010-10-27 CA CA2779009A patent/CA2779009A1/en not_active Abandoned
- 2010-10-27 EA EA201270606A patent/EA024186B1/ru not_active IP Right Cessation
- 2010-10-27 KR KR1020127013564A patent/KR101712231B1/ko active Active
- 2010-10-27 SG SG10201810928SA patent/SG10201810928SA/en unknown
- 2010-10-27 PE PE2012000581A patent/PE20121429A1/es not_active Application Discontinuation
- 2010-10-27 JP JP2012535996A patent/JP5566466B2/ja active Active
- 2010-10-27 AU AU2010310986A patent/AU2010310986A1/en not_active Abandoned
- 2010-10-27 EP EP10782039.1A patent/EP2493466B1/en active Active
- 2010-10-27 PL PL10782039T patent/PL2493466T3/pl unknown
- 2010-10-27 ES ES10782039T patent/ES2862340T3/es active Active
- 2010-10-27 PH PH1/2012/500848A patent/PH12012500848A1/en unknown
- 2010-10-27 DK DK10782039.1T patent/DK2493466T3/da active
- 2010-10-27 WO PCT/IB2010/054866 patent/WO2011051894A1/en not_active Ceased
- 2010-10-27 PT PT107820391T patent/PT2493466T/pt unknown
- 2010-10-27 BR BR112012011457A patent/BR112012011457A2/pt not_active Application Discontinuation
- 2010-10-27 MX MX2012005030A patent/MX336339B/es unknown
- 2010-10-29 AR ARP100103990 patent/AR078824A1/es unknown
- 2010-10-29 UY UY32987A patent/UY32987A/es unknown
- 2010-10-29 TW TW099137327A patent/TWI533866B/zh active
- 2010-10-29 TW TW104143630A patent/TWI654975B/zh active
-
2012
- 2012-04-25 CR CR20120204A patent/CR20120204A/es unknown
- 2012-04-25 TN TNP2012000188A patent/TN2012000188A1/en unknown
- 2012-04-25 IL IL219443A patent/IL219443A0/en unknown
- 2012-04-26 US US13/456,720 patent/US8927592B2/en active Active
- 2012-04-26 GT GT201200123A patent/GT201200123A/es unknown
- 2012-04-27 EC ECSP12011836 patent/ECSP12011836A/es unknown
- 2012-04-27 SV SV2012004192A patent/SV2012004192A/es unknown
- 2012-04-27 NI NI201200071A patent/NI201200071A/es unknown
- 2012-04-30 ZA ZA2012/03123A patent/ZA201203123B/en unknown
- 2012-05-25 MA MA34898A patent/MA33767B1/fr unknown
-
2014
- 2014-06-16 JP JP2014123108A patent/JP6182510B2/ja active Active
- 2014-12-18 US US14/575,578 patent/US20150118182A1/en not_active Abandoned
- 2014-12-18 US US14/575,566 patent/US20150104411A1/en not_active Abandoned
-
2016
- 2016-02-01 AU AU2016200598A patent/AU2016200598A1/en not_active Abandoned
-
2017
- 2017-01-24 IL IL250254A patent/IL250254A0/en unknown
- 2017-06-20 US US15/627,962 patent/US10583110B2/en active Active
- 2017-09-25 AU AU2017232227A patent/AU2017232227B2/en not_active Ceased
-
2019
- 2019-01-18 US US16/251,143 patent/US20190151278A1/en not_active Abandoned
- 2019-05-20 AU AU2019203514A patent/AU2019203514A1/en not_active Abandoned
- 2019-06-23 IL IL267583A patent/IL267583A/en unknown
-
2020
- 2020-01-15 US US16/743,411 patent/US10716777B2/en active Active
- 2020-07-17 US US16/931,802 patent/US20210169843A1/en not_active Abandoned
-
2023
- 2023-07-20 US US18/224,122 patent/US12453712B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2493466T (pt) | Nova utilização antifúngica do cabazitaxel | |
| HRP20182200T1 (hr) | Nova protuupalna sredstva | |
| HUS1900001I1 (hu) | Transztiretin expressziójának módosítása | |
| EP2414948A4 (en) | APPLICATION SHARING | |
| EP2518066A4 (en) | NOVEL THROMBOCYTE AGGREGATION INHIBITOR | |
| EP2552555A4 (en) | CLOTHES OF PHYSICAL CULTURE | |
| BRPI1008346A2 (pt) | inalador | |
| BR112013015602A2 (pt) | nova composição farmacèutica | |
| PT2506716T (pt) | Novos compostos tricíclicos | |
| FI20095251L (fi) | Uudet materiaalit | |
| SMT201400128B (it) | Inalatore | |
| EP2427485A4 (en) | CD133 EPITOPE | |
| BR112012000657A2 (pt) | novos azabicilohexanos | |
| DK2308607T3 (da) | Belægningsstruktur | |
| UY33156A (es) | Nuevos compuestos tienopirrol | |
| BR112012002585A2 (pt) | reforço revestido | |
| DK2434863T3 (da) | Vikleindretning | |
| LT2506840T (lt) | Hipoksija sukeliančio faktoriaus inhibitorių naudojimas | |
| DK2453858T3 (da) | Fremgangsmåde | |
| BR112014005009A2 (pt) | nova prótese intralaríngea | |
| FR2948037B1 (fr) | Materiau photocatalytique | |
| HRP20182083T1 (hr) | Nova kombinacija i uporaba | |
| EP2611453A4 (en) | ANTIMYCOTIC COMPOSITION | |
| IT1402120B1 (it) | Composizione di malta. | |
| FI20096402A0 (fi) | Veriryhmästatuksen käyttö II |